Immune Checkpoint Inhibitor in First-Line Treatment of Metastatic Renal Cell Carcinoma: A Review of Current Evidence and Future Directions

The incidence of renal cell carcinoma (RCC) is rising and metastatic RCC carries a very poor prognosis. The treatment paradigm for metastatic RCC has shifted dramatically in the last decade with multi-targeted tyrosine kinase inhibitors (TKI) previously used as first-line treatment but its utility i...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Iris Tung, Arvind Sahu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2021-08-01
Colecção:	Frontiers in Oncology
Assuntos:	metastatic renal carcinoma immune checkpoint inhibition (ICI) anti-VEGF (vascular endothelial growth factor) agents tyrosine kinase inhibitions (TKIs) therapy biomarker
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2021.707214/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!